EIF2AK3 and neoplasm: To enable future testing of this hypothesis, we sought to create a series of PERK inhibitors with stable PK profiles that could be administered at low doses to attenuate PERK yet tuned through higher doses to sufficiently inhibit PERK for tumor inhibition.